REG - RTW Biotech Opp. - Closed Period Notification

RTW Biotech OpportunitiesAnnouncement

14/08/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240814:nRSN3090Aa&default-theme=true

RNS Number : 3090A  RTW Biotech Opportunities Ltd  14 August 2024

LEI: 549300Q7EXQQH6KF7Z84

14 August 2024

RTW Biotech Opportunities Ltd
(the "Company")

Closed Period Notification

Compliance with the Market Abuse Regulation (MAR)

 

The Company announces that it is satisfied that all inside information which
the directors and the Company may have in the period leading up to the
announcement of the Half-Year Report for the six months ended 30 June 2024 has
been notified to a Regulated Information Service (RIS). The Company is
therefore not prohibited from purchasing its own securities or issuing shares
during the closed period (as defined by MAR) which ends on the date of the
announcement of the Half-Year Report.

If, in the period leading up to the announcement of the Half-Year Report, the
directors of the Company come into possession of any inside information, this
will be notified to a RIS before any such transactions are undertaken.

The closed period will last until the Half-Year Report in respect of the six
months ended 30 June 2024 is published, which is expected to be on or around
13 September 2024.

For Further Information:

 

 RTW Investments, LP                           +44 (0)20 7959 6361
 Woody Stileman, Managing Director

 Krisha McCune, Director, Investor Relations

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKNBDQBKDCFD